26 March 2020 News
The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) for patients with hyperkalaemia, characterised by elevated levels of potassium in the blood. Lokelma is...
9 March 2020 Comment
A proportion of patients with exertional angina and symptoms strongly suggestive of coronary artery disease (CAD) show normal coronary angiograms and are designated as having microvascular angina. Microvascular angina is...
20 February 2020 Comment
Pfizer has announced today that its rare disease oral drug Vyndaqel (tafamidis) has gained a new European Medicines Agency (EMA) approval for expanded use in treating adults with wild-type or...
19 February 2020 Analysis
Due to links between CV, renal and metabolic disease, AstraZeneca has created a joint cardiovascular, renal and metabolic unit to address unmet needs and shared risk factors across the three...
14 February 2020 News
The US Food and Drug Administration (FDA) has requested that Eisai voluntarily withdraw its weight management drug Belviq (lorcaserin) from the US market. Eisai has “submitted a request to voluntarily...
7 February 2020 Comment
On January 31, Esperion Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorisation for...
30 January 2020 Comment
The American Society of Echocardiography recently re-issued guidelines for the use of stress echocardiography in patients with ischemic heart disease (IHD), also known as coronary artery disease (CAD), last updated...
27 January 2020 News
The UK’s National Institute for Health and Care Excellence (NICE) has decided to not recommend National Health Service (NHS) use of Novo Nordisk’s Saxenda (liraglutide).